The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Check It Out: Understanding Immune-Related Adverse Events from Immune Checkpoint Inhibitors

Check It Out: Understanding Immune-Related Adverse Events from Immune Checkpoint Inhibitors

December 4, 2020 • By Jason Liebowitz, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Dr. Cappelli

The Rheumatology Perspective
Laura Cappelli, MD, MHS, MS, assistant professor of medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, spent the remainder of the lecture discussing irAEs, providing clinical pearls for clinicians. Dr. Cappelli noted the spectrum of severity for irAEs runs from mild (i.e., dermatitis, thyroid dysfunction) to severe (i.e., myocarditis, myasthenia gravis, encephalitis).

You Might Also Like
  • Immune-Related Adverse Events with Use of Checkpoint Inhibitors for Immunotherapy of Cancer
  • Immune Checkpoint Inhibitors & Immune-Related Adverse Events
  • Checkpoint Inhibitors May Be Retried after Immune Adverse Event, with Close Monitoring
Also By This Author
  • Without Fear: Psychological Safety for Learners & Patients

She explained that irAEs may develop at different times in relation to starting the ICI medication; indeed, these events may occur soon after starting a medication or may not appear until months or years after initiating treatment, and irAEs have even occurred after the ICI treatment had been discontinued.8 In addition, most—but not all—autoimmune rheumatic diseases have been seen as a result of an irAE, such as inflammatory arthritis, sicca syndrome, myositis and vasculitis, although interestingly, systemic lupus erythematosus appears to be quite rare as an irAE. In one prospective observational study of 60 patients with inflammatory arthritis associated with use of ICIs, persistent arthritis was found to be associated with duration of ICI use, combination ICI therapy, and in patients with multiple other irAEs.9 

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Several organizations, including the American Society of Clinical Oncology (ASCO), the National Comprehensive Cancer Network (NCCN), the Society for Immunotherapy of Cancer (SITC) and the European Society for Medical Oncology (ESMO), have published guidelines on treatment principles with respect to irAEs.

In general, these guidelines advocate for treatment to be guided by the severity of the irAE. The Common Terminology Criteria for Adverse Events (CTCAE) grades irAEs from 1 through 5, with Grade 1 being mild and Grade 5 representing death.10 For a Grade 2 or higher irAE, corticosteroids are typically the first line of treatment. For a Grade 3 or higher irAE, the immune checkpoint inhibitor is typically held or discontinued, in addition to providing corticosteroid treatment. In cases of severe, persistent symptoms and complications of the irAE, in spite of corticosteroids and discontinuation of therapy, treatments that have been used include a range of conventional synthetic disease-modifying anti-rheumatic drugs (DMARDs) and biologic DMARDs.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Cappelli noted that much of the data on how to treat irAEs comes from case reports and small case series and that, in the future, it will be helpful to have more data on the responses to various treatments and the natural history of irAEs to better understand treatment strategies.

An important subject Dr. Cappelli touched on is tumor response related to immunosuppression for irAEs. After all, the indication for an ICI is treatment of a malignancy, and it is important to understand if treating an irAE with immunosuppression will make treatment of the cancer less effective. So far, data are mixed on this subject and mostly limited to short-term exposure to immunosuppression. In one study of nearly 300 patients, treatment with corticosteroids and short-term tumor necrosis factor inhibitor therapy did not affect melanoma therapy with ipilimumab.11 However, in a different study involving nearly 100 patients with melanoma who had ipilimumab-induced hypophysitis, those who received higher doses of glucocorticoids had reduced survival.12 These disparate findings indicate that much more needs to be understood regarding the balance of treating irAEs with the need to effectively treat the underlying malignancy.

Pages: 1 2 3 4 | Single Page

Filed Under: ACR Convergence, Drug Updates, Meeting Reports Tagged With: ACR Convergence 2020, immune checkpoint inhibitor (ICI), Immune checkpoint inhibitors, immunotherapy

You Might Also Like:
  • Immune-Related Adverse Events with Use of Checkpoint Inhibitors for Immunotherapy of Cancer
  • Immune Checkpoint Inhibitors & Immune-Related Adverse Events
  • Checkpoint Inhibitors May Be Retried after Immune Adverse Event, with Close Monitoring
  • Progress on Preventing Immune-Related Adverse Events

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)